# Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

> **NCT03766776** · NA · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Cancer of Liver

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT03766776
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-31
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2018-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03766776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03766776, "Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03766776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*